Recent Research
Stay up-to-date on the advancing field of HCT with short summaries and links to the most relevant published research.
-
Geriatric assessment helps inform decision making and management for older adults with AML
November 2018Loh KP and Klepin HD. Blood Advances - The presenters of this Blood Advances Talk recommend geriatric assessment for older adults with acute myeloid leukemia (AML). They reason that adults of the same age can vary based on underlying health status and physiologic reserve, therefore, decision making and management cannot be optimized using strategies based on chronologic age.
-
Emerging prognostic factors identify older adults with high-risk AML likely to benefit from HCT
November 2018Veltri L, et al. Bio Blood Marrow Transplant - In a recent study, researchers analyzed hematopoietic cell transplant (HCT) outcomes in 185 patients (age >65) with high-risk acute myeloid leukemia (AML) and found the strongest independent risk factor for overall survival (OS) and relapse was associated with achievement of measurable residual disease negative status prior to HCT. Additional prognostic factors identified in this study could help identify patients most likely to benefit from HCT treatment.
-
How I Treat Older Adults with Sickle Cell Disease
October 2018Thein SL and Howard J., Blood Journal – In this installment of the “How I treat…” series, the authors highlight that for patients with sickle cell disease, survival has significantly improved. Consequently, adults face new long-term risks of their disease as well as age-related conditions.
-
Using quality of life to inform treatment decisions for older patients with cancer
September 2018A Task Force of the International Society of Geriatric Oncology recommends all health care professionals involved in the care of older patients with cancer should place a greater focus on quality of life (QOL), and treatment decisions should not be made based on chronological age alone. (Scotté F, et al. Annals of Oncology)
Discover additional QOL recommendations and guidance from the task force
-
Risk-Adapted Treatment Strategies for Older Patients with AML
July 2018Arellano M, et al. Cancer – In this review, the authors argue that the current treatment algorithm for older patients with acute myeloid leukemia (AML) ─ induction, followed by consolidation (with or without transplantation) versus hospice ─ is no longer sufficient. -
Allogeneic HCT is Feasible for Patients Aged ≥70 Years
June 2018Al Malki MM, et al. Biol Blood Marrow Transplant – Patients aged 70 years and older undergoing reduced-intensity allogeneic HCT can achieve 2-year overall survival rates of 68%. -
Frailty Assessments Can Inform Treatment Decisions in Patients with Hematologic Malignancies
March 2018Abel GA, et al. Blood – In this review, the authors outline how hematologists can make better treatment recommendations for their patients by incorporating several easy-to-use frailty assessment tools into their practice. -
Study Shows Age Doesn't Affect Survival Outcomes in Patients with Non-Hodgkin Lymphoma Who Undergo Allogeneic HCT
February 2018Results from a retrospective study presented at the 2018 BMT Tandem Meetings dispute age as a limiting factor to transplant eligibility, showing no differences in 4-year outcomes for patients older or younger than age 65.
-
Measuring Frailty Can Improve Existing Prognostic Tools
December 2017Hegde A, et al. Bone Marrow Transplant – Because frailty is prevalent in many patients pre- and post-transplant and is associated with age-independent adverse transplant outcomes, the authors of this review recommend incorporating a frailty assessment to optimize the predictive ability of existing pre-transplant assessment (PTA) tools across all age groups and particularly in elderly individuals. -
Disease Risk Index is Important Prognostic Factor for Older HCT Patients
September 2017He F, et al. Biol Blood Marrow Transplant – A study of 196 patients age 60-75 years with hematologic malignancies undergoing reduced-intensity conditioning (RIC) hematopoietic cell transplantation (HCT) has found that the Disease Risk Index (DRI) score is a significant prognostic factor for post-transplant relapse, treatment failure and mortality. -
Older Patients with MDS: Uncovering Barriers to Allogeneic HCT
August 2017Getta BM, et al. Biol Blood Marrow Transplant – Only one-third of all patients with myelodysplastic syndromes (MDS) referred to an academic center undergo hematopoietic cell transplantation (HCT), according to a study of 362 patients with MDS treated at Memorial Sloan Kettering Cancer Center. -
Improved Outcomes and Increased Use of HCT in Patients ≥70 Years
August 2017Muffly L, et al. Blood – Overall and progression-free survival after allogeneic hematopoietic cell transplantation (HCT) in patients ≥70 years with hematologic malignancies increased significantly between 2000 and 2013, according to a multi-center study. -
Patients with MDS Responding to HMAs Have Better HCT Outcomes
July 2017Festuccia M, et al. Biol Blood Marrow Transplant – Patients with myelodysplastic syndromes (MDS) who undergo hematopoietic cell transplantation (HCT) while still responding to hypomethylating agents (HMAs) have lower rates of post-HCT relapse, according to a study of 125 patients with MDS. -
Comorbidity Scores are Prognostic of Overall Survival in Relapsed/Refractory AML
July 2017Middeke JM, et al. Biol Blood Marrow Transplant – Comorbidity evaluations can provide clinically useful prognostic information at the time of diagnosis of relapsed or refractory acute myeloid leukemia (AML), according to results of a phase II trial. -
Cytogenetic Risk Prognostic of HCT Outcomes in Older Patients with AML in CR2
May 2017Michelis FV, et al. Cancer – Allogeneic hematopoietic cell transplantation (HCT) is a curative treatment option for older patients with acute myeloid leukemia (AML) in second complete remission (CR2), particularly for those with favorable or intermediate cytogenetic risk, according to researchers who studied 169 transplants at 78 centers. -
Allogeneic HCT is Feasible for Patients ≥70 Years
April 2017Sorror ML, et al. Biol Blood Marrow Transplant – New research presented at the BMT Tandem Meetings shows that patients aged 70 years and older can have comparable hematopoietic cell transplantation (HCT) outcomes to those of younger patients and that comorbidities and disease risks, not age, should be used to evaluate potential candidates. -
Comparable HCT Survival and Incidence of Toxicity for Patients ≥60 Years
December 2016Shah GL, et al. ASH abstract oral presentation, December 2016 – Survival of patients ≥60 years undergoing ex vivo CD34+ selected reduced-intensity hematopoietic cell transplantation (HCT) was comparable to that of patients <60 years, according to research presented at ASH. -
Careful Selection of Older Patients with MDS Can Improve HCT Outcomes
November 2016Heidenreich S, et al. Biol Blood Marrow Transplant – Researchers analyzing 313 patients over age 70 (median age 72 years) whose transplant outcomes were reported to the registry of the European Society for Blood and Marrow Transplantation (EBMT) found that careful selection of patients can significantly improve hematopoietic cell transplantation (HCT) outcomes. -
Review: Advances in Allo-HCT Expand Use in Older Patients with NHL
May 2016Fenske TS, et al. Biol Blood Marrow Transplant – In this review, the authors present data supporting allogeneic HCT as a therapeutic option for patients with non-Hodgkin lymphoma (NHL) diffuse large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma focusing on patients over age 60. -
Decision-Making Recommendations for Older Adults Considering HCT
April 2016Randall J, et al. Bone Marrow Transplant – This article outlines strategies to help older adults make an informed decision about transplantation, recognizing that older adults will likely have different functional and psychosocial considerations at this stage in life. -
Increased Use of and Improved Survival in HCT for Patients ≥70 Years
February 2016Muffly L, et al. BMT Tandem Meetings abstract oral presentation, February 2016 – A study of 1,106 patients ≥70 years undergoing allogeneic hematopoietic cell transplantation (HCT) between 2000 and 2013 has found that overall survival has improved significantly and use of HCT in this patient cohort has increased over the last decade. -
Review: HCT for Patients with AML in First Complete Remission
January 2016Cornelissen JJ, et al. Blood – In this review, part of a Blood journal special review series on acute myeloid leukemia (AML), the authors note that although the majority of patients AML enter remission upon induction chemotherapy, the risk of relapse is considerable and it varies greatly according to age and genetic subtype. -
Patients Age 65 Years and Older with MDS Should Not Be Limited from Undergoing HCT
December 2015Atallah E, et al. ASH abstract oral presentation, December 2015 – Patients over age 65 with myelodysplastic syndromes (MDS) should be considered transplant eligible, according to an oral presentation at the 2015 ASH Annual Meeting. -
Meta-Analysis: Age Not a Determining Factor in HCT Selection for AML
November 2015Rashidi A, et al. Biol Blood Marrow Transplant – A meta-analysis of 749 patients >60 years undergoing hematopoietic cell transplantation (HCT) for acute myeloid leukemia (AML) has shown that older age per se should not be the sole criterion against selecting HCT therapy. -
Low Non-Relapse Mortality, GVHD after HCT in Older Patients with AML in First Remission
November 2015Devine SM, et al. J Clin Oncol – A multi-center phase II study of 114 patients aged 60-74 years with AML in first remission has found that reduced-intensity HCT can lead to a low incidence of non-relapse mortality (NRM) and graft-versus-host disease (GVHD). -
HCT Yields Best Outcomes in Patients ≥60 Years with AML
October 2015Versluis J, et al. Lancet Haematol – A study analyzing a series of four multi-center trials has shown significantly better 5-year overall survival for allogeneic hematopoietic cell transplantation (HCT) in patients aged 60 years and older with acute myeloid leukemia (AML) when compared with no and other post-remission therapies. -
AML patients ≥70 Achieve 60% Estimated Survival with UCB HCT
October 2015Sandhu KS, et al. Biol Blood Marrow Transplant – In this single-center retrospective study of 22 transplant recipients 70 years and older, 10 patients undergoing umbilical cord blood (UCB) transplantation had an estimated 2-year overall survival of 60%. -
Non-Myeloablative Haploidentical HCT in Older Patients
September 2015Kasamon YL, et al. J Clin Oncol – This retrospective, single-center study found that age had no significant effect on survival of 271 patients age 50-75 years undergoing non-myeloablative haploidentical hematopoietic cell transplantation (HCT). -
Younger Donor Age Correlates with Higher CD-8 T Cell Counts, Better HCT Outcomes
April 2015Reshef R, et al. Oral presentation BMT Tandem Meetings — New research presented at the BMT Tandem Meetings has shown that younger donor age correlates with higher CD-8 T cell counts, and that more CD-8 T cells lead to significantly better HCT outcomes. -
No Impact of Patient Age on Survival in Reduced-Intensity HCT
March 2015Federmann B, et al. Bone Marrow Transplant — Patient age has no significant impact on survival, according to results of a retrospective study of 151 patients aged ≥60 undergoing reduced-intensity allogeneic HCT with related and unrelated donors between 2000 and 2012. -
Review: How I Treat the Older Patient with AML
January 2015Ossenkopple G, et al. Blood – In this installment of the “How I treat” series in Blood, the authors discuss the highly heterogeneous clinical biology of acute myeloid leukemia (AML) among patients and how those variations are relevant for prognosis and treatment choice. -
Progress Report: Update of BMT CTN State of the Science Symposium
February 2014Ferrara JLM. Biol Blood Marrow Transplant – In this 2014 report, the author updates the status of the 11 hematopoietic cell transplantation (HCT) clinical trials identified as having the highest scientific priority at the 2007 State of the Science Symposium convened by the Blood and Marrow Transplant Clinical Trials Network (BMT CTN).